中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Changes in alpha-fetoprotein and des-γ-carboxy-prothrombin after transarterial chemoembolization and their value in predicting treatment outcome

DOI: 10.3969/j.issn.1001-5256.2019.01.020
Research funding:

 

  • Published Date: 2019-01-20
  • Objective To investigate the value of alpha-fetoprotein (AFP) combined with des-γ-carboxy-prothrombin (DCP) in predicting the therapeutic effect of transarterial chemoembolization (TACE) .Methods A retrospective analysis was performed for the clinical data of 85 patients with hepatocellular carcinoma (HCC) who underwent TACE in The First Affiliated Hospital of Soochow University from October 2016 to March 2018.The serum levels of AFP and DCP were measured before TACE and after two consecutive sessions of TACE, and modified RECIST (mRECIST) was used to evaluate the therapeutic effect of TACE.The changes in AFP and DCP were compared with imaging findings based on mRECIST.The two-independent-samples t test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups.The chi-square test was used for comparison of categorical data between two groups, and the Mann-Whitney U test was used for comparison of ranked data between two groups.A Spearman correlation analysis was used to investigate the correlation of mRECIST category with AFP and DCP.The receiver operating characteristic (ROC) curve was used to investigate the value of each index in the diagnosis of remission.Results According to the mRECIST criteria, 38 patients achieved remission (remission group) and 31 did not achieve remission (non-remission group) .After treatment, the remission group had significantly lower AFP and DCP than the non-remission group (Z=-3.366 and-4.065, both P<0.05) .There were significant differences between the remission group and the non-remission group inΔAFP, ΔDCP, ΔAFP%, andΔDCP% (Z=-4.837, -5.597, -4.210, and-5.851, all P<0.001) .The mRECIST category was negatively correlated withΔAFP andΔDCP (rs=-0.552 and-0.593, both P<0.001) .In the diagnosis of remission, ΔAFP%had an area under the ROC curve (AUC) of 0.796, whileΔDCP%had an AUC of 0.912 andΔAFP%combined withΔDCP%had an AUC of0.921, suggesting thatΔAFP%combined withΔDCP%had the highest diagnostic value.Conclusion Changes in serum DCP and AFP after TACE can be used to evaluate the outcome of HCC after TACE.

     

  • [1]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132.
    [2]RAOUL JL, SANGRO B, FORNER A, et al.Evolving strategies for the management of intermediate-ate-stage hepatocellular carcinoma:Available evidence and expert opinion on the use of transarterial chemoembolization[J].Cancer Treat Rev, 2011, 37 (3) :212-220.
    [3]LIANG YF, SHI L, SUN NN, et al.Analysis of the dynamic changes and clinic significance of serum CA724, CA242 and AFP levels before and after TACE treatment of primary hepatic carcinoma[J].Tianjin Med J, 2015, 43 (10) :1183-1186. (in Chinese) 梁育飞, 石亮, 孙宁宁, 等.CA724、CA242及AFP在肝癌TA-CE治疗前后的表达变化及临床意义[J].天津医药, 2015, 43 (10) :1183-1186.
    [4]CUI HZ, WANG MC, XU AF, et al.Correlation analysis of alpha fetoprotein changes and therapeutic effect after transcatheter arterial chemoembolization[J].Chin J Health Lab Technol, 2018, 28 (10) :1220-1222. (in Chinese) 崔怀中, 王妙婵, 徐爱芳, 等.肝动脉栓塞化疗术后甲胎蛋白变化与疗效的相关性分析[J].中国卫生检验杂志, 2018, 28 (10) :1220-1222.
    [5]LIN YY, CHEN Y, CHEN YS, et al.Clinical value of the abnormal prothrombin PVKIA-Ⅱin detection of hepatocellular carcinoma[J].Curr Immunol, 2015, 35 (4) :328-333. (in Chinese) 林莺莺, 陈燕, 陈岩松, 等.异常凝血酶原 (PIVKA-Ⅱ) 检测在肝细胞癌中的临床价值[J].现代免疫学, 2015, 35 (4) :328-333.
    [6]National Health and Family Planning Commission of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) .中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.
    [7] OKEN MM, CREECH RH, TORMEY DC, et al.Toxicity and response criteria of the eastern cooperative oncology group[J].Am J Clin Oncol, 1982, 5 (6) :649-655.
    [8]LENCIONI R, LLOVET JM.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J].Semin Liver Dis, 2010, 30 (1) :52-60.
    [9]SUN ZD, CHENG LM, PING P, et al.Analysis of the risk factors for prognosis of surgical treatment patients with primary liver cancer[J].J Clin Exp Med, 2017, 16 (12) :1204-1207. (in Chinese) 孙志德, 程利民, 平萍, 等.影响原发性肝癌患者手术治疗预后的危险因素分析[J].临床和实验医学杂志, 2017, 16 (12) :1204-1207.
    [10]XIA DD, WANG EX, WANG WJ, et al.Early alpha-fetoprotein response can predict the prognosis of patients with intermediate-stage hepatocellular carcinoma trated with transarterial chemoembolization[J].J Clin Hepatol, 2017, 33 (6) :1120-1125. (in Chinese) 夏冬东, 王恩鑫, 王文军, 等.早期AFP应答对经肝动脉化疗栓塞术后中期肝细胞癌患者预后的预测价值[J].临床肝胆病杂志, 2017, 33 (6) :1120-1125.
    [11]ZHENG HL, ZHAO R, LI DP, et al.Utility of DCP and AFP in diagnosis of primary liver cancer[J].Chin J Gen Prac, 2016, 14 (1) :29-31. (in Chinese) 郑海伦, 赵睿, 李大鹏, 等.肿瘤标志物DCP和AFP在原发性肝癌中的诊断价值[J].中华全科医学, 2016, 14 (1) :29-31.
    [12]LIEBMAN HA, FURIE BC, TONG MJ, et al.Des-g-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma[J].N Engl J Med, 1984, 310 (22) :1427-1431.
    [13]WANG QS.Application of serum abnormal prothrombin and alpha-fetoprotein in the diagnosis of primary hepatic carcinoma[J].J Shenyang Med Coll, 2017, 19 (4) :336-338. (in Chinese) 王全胜.血清异常凝血酶原和甲胎蛋白在原发性肝癌诊断中的应用[J].沈阳医学院学报, 2017, 19 (4) :336-338.
    [14]ZHENG HL, ZHAO R, LI DP, et al.The significance of the level changes of serum DCP and AFP before and after the intervention treatment in patients with primary hepatic carcinoma[J].Acta Acad Med Bengbu, 2014, 39 (8) :1012-1014. (in Chinese) 郑海伦, 赵睿, 李大鹏, 等.原发性肝癌患者介入治疗前后血清异常凝血酶原和甲胎蛋白变化的意义[J].蚌埠医学院学报, 2014, 39 (8) :1012-1014.
    [15]ZHANG QL, XING XZ, ZHANG LY, et al.Clinical value of combined detection of pokemon, AFP-L3, AFP and DCP after transarterial chemoembolization for hepatocellular carcinoma[J].Anhui Med Pharm J, 2017, 21 (3) :468-471. (in Chinese) 张全乐, 邢喜芝, 张立英, 等.肝癌介入治疗前后原癌基因Pokemon、甲胎蛋白异质体、甲胎蛋白、脱γ-羧基凝血酶原联合检测的临床价值[J].安徽医药, 2017, 21 (3) :468-471.
    [16]ICHIKAWA T, MACHIDA N, SASAKI H, et al.Early prediction of the outcome using tumor markers and mRECIST in unresectable hepatocellular carcinoma patients who underwent transartery chemoembolization[J].Oncology, 2016, 91 (6) :317-330.
    [17]ARAI T, KOBAYASHI A, OHYA A, et al.Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization[J].Int J Clin Oncol, 2014, 19 (5) :871-879.
    [18]PARK WH, SHIM JH, HAN SB, et al.Clinical utility of des-γ-car-boxy prothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J].J Vasc Interv Radiol, 2012, 23 (7) :927-936.
    [19]ZHAO CH, ZHOU WF, CHEN WH, et al.Clinical significance ofα-fetoprotein in initial diagnosis of primary hepatic cancer?[J].J Clin Hepatol, 2013, 29 (9) :698-701. (in Chinese) 赵春华, 周文峰, 陈维华, 等.甲胎蛋白在原发性肝癌首诊中的价值[J].临床肝胆病杂志, 2013, 29 (9) :698-701.
    [20]HU B, TIAN X, SUN J.Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma:A meta-analysis[J].Int J Mol Sci, 2013, 14 (12) :23559-23580.
    [21]WU B, ZHOU J, LING G, et al.Calli Spheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma:A short-term efficacy and safety study[J].World J Surg Oncol, 2018, 16 (1) :69.
  • Relative Articles

    [1]Yanhong BAO, Qiang WANG, Wenlong ZHANG, Na GE, Nan LI, Jun SU, Kexin LI. Ursolic acid in Hippophae rhamnoides L. inhibits hepatocyte apoptosis in rats with alcoholic liver disease by regulating mitochondria-cytochrome c[J]. Journal of Clinical Hepatology, 2023, 39(7): 1617-1626. doi: 10.3969/j.issn.1001-5256.2023.07.016
    [2]Ruibin WANG, Yuzheng LU, Jinglin ZHU, Wei WANG, Guang JIA. Inhibitory effect of lidocaine on Kupffer cell inflammatory response and its effect on liver abscess formation in diabetic mice[J]. Journal of Clinical Hepatology, 2022, 38(6): 1341-1346. doi: 10.3969/j.issn.1001-5256.2022.06.023
    [3]Jianan ZHAO, Jinghua PENG, Ping LIU, Yiyang HU. Effect of Cordyceps polysaccharides on hepatocyte apoptosis induced by tumor necrosis factor-α[J]. Journal of Clinical Hepatology, 2021, 37(6): 1368-1372. doi: 10.3969/j.issn.1001-5256.2021.06.029
    [4]Bi YanZhen, Zhang QiuSheng, Fan Zeng, Yang YongHong, Zhang XiaoBei, Wang QuanQuan, Wang QuanYi, Wang YiBo, Duan ZhongPing, Chen Yu, Shu ZhenFeng, Si ChuanPing, Hong Feng. Effect of human liver-derived stem cells in prevention and treatment of alcoholic fatty liver disease in mice[J]. Journal of Clinical Hepatology, 2019, 35(3): 592-595. doi: 10.3969/j.issn.1001-5256.2019.03.027
    [5]Gong Jing, Jie XinKe. Effect of endoplasmic reticulum stress and autophagy on hepatocyte apoptosis[J]. Journal of Clinical Hepatology, 2019, 35(12): 2828-2832. doi: 10.3969/j.issn.1001-5256.2019.12.041
    [6]Pan Jing, Pan WenTing, Wu LiHui. Expression and significance of Th22 cells and its functional factor interleukin-22 in mice with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1745-1749. doi: 10.3969/j.issn.1001-5256.2018.08.030
    [7]Gao Si, Zhao XiangXuan, Lu ZaiMing. Role of cell apoptosis regulated by P53 in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(7): 1373-1376. doi: 10.3969/j.issn.1001-5256.2017.07.038
    [8]Zhang ChaoYa, Zhao XiangXuan, Lu ZaiMing, Guo QiYong. Research advances in sorafenib- induced apoptotic signaling pathways in liver cancer cells[J]. Journal of Clinical Hepatology, 2016, 32(4): 816-820. doi: 10.3969/j.issn.1001-5256.2016.04.048
    [9]Pan LiuLan, Jia ShengNan, Ma JingTing, Tai JingHua, Jin ZhenJing. Effect of decoy receptor 3 gene on hepatocyte apoptosis[J]. Journal of Clinical Hepatology, 2016, 32(7): 1330-1333. doi: 10.3969/j.issn.1001-5256.2016.07.023
    [10]Zhang Xu, Wang Yu, Ma Juan, Wang ZhenZhen, Yuan Juan, Ma Yan, Liu Xin. Role of endoplasmic reticulum stress-mediated apoptosis in liver fibrosis[J]. Journal of Clinical Hepatology, 2015, 31(9): 1537-1539. doi: 10.3969/j.issn.1001-5256.2015.09.044
    [11]Peng Yuan, Tao YanYan, Huang Kai, Zhao Qiang, Liu ChengHai. Regulatory effect of poly I∶C on intrahepatic natural killer cells in mouse model of liver injury induced by carbon tetrachloride[J]. Journal of Clinical Hepatology, 2015, 31(12): 2077-2083. doi: 10.3969/j.issn.1001-5256.2015.12.022
    [12]Pan YuanWei, Ping Jian, Xu LieMing. Research advances in main signaling pathways for inducing apoptosis of activated hepatic stellate cells[J]. Journal of Clinical Hepatology, 2014, 30(2): 182-185. doi: 10.3969/j.issn.1001-5256.2014.02.021
    [13]Wang XiXun, Jiang LiXin, Wang JingLin, Liang Jing, Zhai HuiYuan, Xia XianMing. Experimental study on hepatocyte apoptosis induced by acute biliary tract infection[J]. Journal of Clinical Hepatology, 2014, 30(11): 1164-1168. doi: 10.3969/j.issn.1001-5256.2014.11.018
    [14]Weng ShanGeng, Xu ChangGuo, Sun Ying, Shi Zheng, Lin LiJuan. Study on the apoptosis of rat hepatic stellate cells induced by kapamycin[J]. Journal of Clinical Hepatology, 2012, 28(3): 219-222.
    [15]Qiao ChunPing, Chen YueXiang. Advances in study of the relationship between apoptosis and alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 386-390.
    [16]Zhang LiLi, Guo XiaoHong, Liu LiXin, Zhang QianQian. IGFBPrP1 siRNA induced apoptosis in rat hepatic stellate cells and its mechanism[J]. Journal of Clinical Hepatology, 2011, 27(9): 965-969+979.
    [17]Zhang Biao, Sui Tao, Yu XiuYing, Cao YongXian, Yao Yuan, He Hong. Significance of detecting apoptosis of PBMC and cytokine of supernatant induced by PHA in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2004, 20(3): 138-140.
  • Cited by

    Periodical cited type(4)

    1. 冯婧,高洪燕,黄山. 生化指标及自身抗体对原发性胆汁性肝硬化的诊断价值. 分子诊断与治疗杂志. 2021(07): 1039-1042 .
    2. 刘蓉,陈清,熊美娥. 肝硬化门静脉高压患者的超声特点. 中国当代医药. 2019(22): 141-143 .
    3. 董征. 原发性胆汁性肝硬化与病毒性肝炎肝硬化超声诊断的对比研究. 当代医学. 2019(29): 105-107 .
    4. 杨璐萍,朱宗国,张然. 原发性胆汁性肝硬化患者免疫功能及肝功能损伤情况研究. 国际检验医学杂志. 2017(18): 2543-2545 .

    Other cited types(2)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1891) PDF downloads(334) Cited by(6)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return